Table 4.
Frequencies of Post-COVID-19 Vaccination Local Signs and Symptoms by Dose.
| Local Signs and Symptoms | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaccine Name | N | N | Pain N (%) |
Tenderness N (%) |
Redness N (%) |
Bruising N (%) |
Swelling N (%) |
Petechia N (%) |
Itching N (%) |
Firmness N (%) |
Swollen Lymph Nodes N (%) |
|||||||||
| FD | SD | FD | SD | FD | SD | FD | SD | FD | SD | FD | SD | FD | SD | FD | SD | FD | SD | FD | SD | |
| Sputnik V | 683 | 667 | 305 (44.7) | 219 (32.8) | 143 (20.9) | 59 (8.8) | 19 (2.8) | 3 (0.4) | 3 (0.4) | 8 (1.2) | 27 (4) | 11 (1.6) | 4 (0.6) | 2 (0.3) | 3 (0.4) | 3 (0.4) | 44 (6.4) | 18 (2.7) | 4 (0.6) | 3 (0.4) |
| Sinopharm | 325 | 314 | 127 (39.1) | 83 (26.4) | 53 (16.3) | 26 (8.3) | 2 (0.6) | 5 (1.6) | 1 (0.3) | 0 (0.0) | 6 (1.8) | 4 (1.3) | 0 (0) | 0 (0) | 3 (0.9) | 0 (0) | 11 (3.4) | 4 (1.3) | 0 (0.0) | 0 (0.0) |
| Oxford AstraZeneca | 274 | 270 | 160 (58.4) | 131 (48.5) | 112 (40.9) | 85 (31.5) | 17 (6.2) | 4 (1.5) | 6 (2.2) | 6 (2.2) | 31 (11.3) | 12 (4.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.7) | 45 (16.4) | 17 (6.3) | 0 (0.0) | 0 (0.0) |
| Covaxin | 140 | 137 | 62 (44.3) | 36 (26.3) | 44 (31.4) | 16 (11.7) | 2 (1.4) | 1 (0.7) | 1 (0.7) | 3 (2.2) | 23 (16.4) | 3 (2.2) | 2 (1.4) | 1 (0.7) | 1 (0.7) | 3 (2.2) | 21 (15) | 7 (5.1) | 1 (0.7) | 1 (0.7) |
| COVIran Barekat | 78 | 78 | 12 (15.4) | 5 (6.4) | 34 (43.6) | 14 (17.9) | 2 (2.6) | 0 (0) |
0 (0) |
0 (0) |
5 (6.4) | 3 (3.8) | 0 (0) |
0 (0) |
1 (1.3) | 0 (0) |
2 (2.6) | 1 (1.3) | 0 (0.0) | 0 (0.0) |
| Total | 1500 | 1466 | 666 (44.4) | 474 (31.6) | 386 (25.7) | 200 (13.6) | 42 (2.8) | 13 (0.9) | 11 (0.7) | 17 (1.2) | 92 (6.1) |
33 (2.3) | 6 (0.4) | 3 (0.2) | 8 (0.5) | 8 (0.5) | 123 (8.2) | 47 (3.2) | 5 (0.3) | 4 (0.3) |
| χ2p-Value | <0.001 | <0.001 | <0.001 | <0.001 | 0.001 | 0.282 | 0.037 | 0.074 | <0.001 | 0.055 | 0.134 | 0.477 | 0.489 | 0.055 | <0.001 | 0.004 | 0.382 | 0.458 | ||
N: number of participants; FD: first dose; SD: second dose.